The Ipswich Touch Test (IpTT) is a simple, equipment‑free screening tool designed to detect loss of protective sensation in the feet of people with diabetes, supporting early identification of those at risk of ulceration and amputation.
Background and Rationale
Diabetic peripheral neuropathy (DPN) is one of the most important risk factors for diabetic foot ulceration and subsequent amputation, making early detection of sensory loss a central goal of foot screening programs. Standard tools such as the 10 g Semmes–Weinstein monofilament and vibration perception threshold testing are well established, but they require equipment, may not always be available, and are underused in busy or resource‑limited settings. The IpTT was developed by Rayman and colleagues at Ipswich Hospital (UK) after they observed inadequate foot screening of inpatients with diabetes, which was associated with preventable heel ulcers. Their aim was to design a safe, quick, low‑cost test that could be performed by any health‑care worker at the bedside, thereby embedding foot protection into routine inpatient care.
Test Procedure and Interpretation
The Ipswich Touch Test involves light touch of specific toes and relies on patient perception rather than instrument‑based stimulation. With the patient lying or sitting and eyes closed, the examiner uses the index finger to lightly touch the tips of the first, third, and fifth toes on each foot (six sites in total) for approximately 1–2 seconds, taking care not to press harder if the patient does not initially respond and touching each site only once. After each touch, the patient is asked to say when and where they feel the stimulus; their responses are recorded as “felt” or “not felt” at each site. Loss of protective sensation is generally defined as two or more insensate sites out of the six tested, a cut‑off that has been used in multiple validation studies and correlates with elevated risk of ulceration.
The simplicity of the procedure confers several practical advantages. The examiner’s finger is always available, easily cleaned, and does not bend or wear out like monofilaments, eliminating the need for replacement or calibration. Only brief training is needed to standardise touch pressure and timing, allowing nurses, care assistants, and even family members to learn and perform the test reliably. This low barrier to implementation is particularly valuable on general hospital wards, in primary care, and in remote or resource‑limited settings where specialised equipment may be unavailable.
Evidence on Diagnostic Performance
Rayman et al. originally compared the IpTT with the 10 g monofilament and vibration perception threshold (VPT) ≥ 25 V as a reference standard in 265 individuals with diabetes. Using a threshold of at least two insensate sites, they reported IpTT sensitivity of 77% and specificity of 90% for identifying feet at risk, compared with monofilament sensitivity of 81% and specificity of 91%; agreement between IpTT and monofilament was almost perfect, with a kappa of 0.88. Inter‑rater agreement for the IpTT itself was substantial (kappa 0.68), supporting its reliability when performed by different examiners. Subsequent studies have broadly confirmed these performance characteristics, though reported sensitivity varies, reflecting differences in populations, reference standards, and settings.
A key piece of evidence is the systematic review and meta‑analysis by Hu et al., which pooled data from five studies using the 10 g monofilament as the reference. They found pooled sensitivity of 0.77 and specificity of 0.96, with an area under the summary receiver‑operating characteristic curve of 0.897, indicating high overall diagnostic accuracy for detecting loss of protective sensation. When compared against VPT ≥ 25 V, IpTT sensitivity ranged from 76–100% and specificity from 90–96.6%, again suggesting strong agreement with more equipment‑dependent measures. Other individual studies have reported sensitivities spanning roughly 51–93% and specificities in the 90–98% range when benchmarked against monofilament, pinprick, and neuropathy disability scores, reinforcing the view that a positive IpTT is highly specific for neuropathy even where sensitivity may be more modest
Home‑based and lay‑person application has also been studied. In one cohort of 331 patients, 25.1% had at least two insensate sites on monofilament testing; a home‑performed IpTT achieved sensitivity of 78.3%, specificity of 93.9%, positive predictive value of 81.2%, and negative predictive value of 92.8% for detecting “at‑risk” feet. Another study reported 100% agreement between IpTT performed at home by a friend or family member and clinical testing, highlighting the potential for self‑monitoring and community‑based screening models. More recent work continues to support good specificity (often above 95%) but notes that sensitivity can be relatively low in some series, making the IpTT better at confirmatory identification of neuropathy than at ruling it out in isolation.
Clinical Applications and Advantages
In clinical practice, the Ipswich Touch Test can be integrated into diabetic foot assessment across multiple settings. In hospital, it provides an immediate, no‑equipment method to identify inpatients needing pressure relief and close monitoring, helping reduce the incidence of heel ulcers and other iatrogenic lesions. In primary care and diabetes clinics, it serves as a rapid screening tool that can be routinely applied by nurses or podiatrists, prompting more detailed neurological assessment and preventive interventions when abnormal. Its ease of teaching also makes it attractive for structured self‑care programs, where patients and carers are encouraged to perform regular home checks in between professional visits.
The main advantages of the IpTT are its simplicity, negligible cost, portability, and minimal training requirements. It is inherently infection‑control friendly, as the examiner’s hands can be washed or gloved, contrasting with reusable tuning forks or shared monofilaments that may require more specific decontamination processes. In many low‑ and middle‑income settings where monofilaments, tuning forks, or biothesiometers are unavailable or unaffordable, the IpTT offers a pragmatic way to introduce neuropathy screening and begin risk‑stratified foot care. Even in well‑resourced environments, its speed and convenience lower the threshold for screening, potentially raising coverage among people with diabetes who might otherwise be missed.
Limitations and Role in Comprehensive Assessment
Despite these strengths, several limitations must be acknowledged. The IpTT is inherently subjective, relying on patient report and examiner consistency, and it does not quantify threshold intensity or distinguish between small‑ and large‑fiber neuropathy in the way that more detailed neurological testing can. Variability in sensitivity across studies suggests that a normal Ipswich Touch Test, especially when performed by non‑specialists, does not fully exclude neuropathy, and therefore it should not replace 10 g monofilament testing or VPT where these are available. Some comparative data indicate that monofilaments may detect neuropathy earlier or more comprehensively, leading several authors to conclude that Ipswich Touch Test is best regarded as an ideal alternative in the absence of monofilaments rather than a superior test.
For podiatrists and multidisciplinary diabetic foot teams, the Ipswich Touch Test should therefore sit within a broader assessment framework. A comprehensive foot exam will typically combine visual inspection, vascular assessment, monofilament or VPT testing, evaluation of deformity and footwear, and assessment of previous ulcer or amputation history, with Ipswich Touch Test functioning as an adjunct or backup. In resource‑limited contexts, using IpTT as a primary screen, possibly combined with another simple neurological sign such as ankle reflex or vibration, may enhance sensitivity while preserving the benefits of a low‑cost approach. Ultimately, the value of the Ipswich Touch Test lies less in technological sophistication and more in its capacity to democratise neuropathy screening and embed foot protection into everyday care for people with diabetes.